The Full Wiki



More info on MVA85A

MVA85A: Wikis
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

Updated live from Wikipedia, last check: June 03, 2012 01:19 UTC (41 seconds ago)

From Wikipedia, the free encyclopedia

MVA85A (modified vaccinia Ankara 85A) is a new-generation vaccine against tuberculosis developed by researchers at Oxford University. This vaccine produces higher levels of long-lasting cellular immunity when used together with the old TB vaccine called BCG.[1] Phase I clinical trials have been completed[2] and phase II clinical trials are currently underway in South Africa with the aim of achieving a product licence by 2010.[3]

External links

References

  1. ^ McShane H, Pathan AA, Sander CR, et al. (2004). "Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired anti-microbial immunity in humans". Nat Med 10: 1240–44. doi:10.1038/nm1128.  
  2. ^ Hawkridge T, Scriba TJ, Gelderbloem, et al. (2008). "Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa". J Infect Dis 198: 544–52. doi:10.1086/590185.  
  3. ^ Ibanga H, Brookes R, Hill P, Owiafe P, Fletcher H, Lienhardt C, Hill A, Adegbola R, McShane H (2006). "Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design". Lancet Infect Dis 6 (8): 522–8. doi:10.1016/S1473-3099(06)70552-7. PMID 16870530.  
Artificial induction of immunity / Immunization: Vaccines, Vaccination, and Inoculation (J07)
Development
Administration
Global: GAVI Alliance · Policy · Schedule · Vaccine injury
USA: ACIP · VAERS · VSD · Vaccine court
Vaccines
Bacterial
Viral
Protozoan
Other
Controversy
See also







Got something to say? Make a comment.
Your name
Your email address
Message
Please enter the solution to case below
70+12=